Drug intelligence / Profile preview

CLS-015

Development stage: Phase 1
Lead developer: Tel Aviv Sourasky Medical Center
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

CLS-015 is a recombinant human deoxyribonuclease I (rhDNase I) being developed by Tel-Aviv Sourasky Medical Center. It is designed to degrade extracellular DNA, specifically targeting neutrophil extracellular traps (NETs) within the tumor microenvironment. The drug is currently being evaluated in a Phase 1 clinical trial as an adjunctive therapy to anti-CD19 CAR-T cell therapy for patients with stable or progressive large B-cell lymphoma (LBCL) at the time of lymphodepletion. The rationale for this combination is that NETs can create a physical and biochemical barrier that impairs the infiltration and function of CAR-T cells; by degrading these structures, CLS-015 aims to enhance the efficacy and safety of the cellular immunotherapy.

Other names: rhDNase Irecombinant human DNase I

Targets

eDNA (Extracellular DNA)

Beyond the preview

Go deeper on CLS-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLS-015.

Explore the full profile